In recent times gene therapy has emerged as an interesting field for a range of treatments and naturally there is considerable interest among investors in companies which are involved in that space.
One of the companies that could be worth watching is Genprex Inc. (NASDAQ:GNPX). On Wednesday, the Genprex stock was in considerable focus and soared by as much as 13% following a key announcement from the company. The company announced that the all comments regarding the Acclaim 1 clinical trial for one of its therapies have been confirmed and reviewed by the United States Food and Drug Administration.
The trial in question is going to be for the company’s main candidate REQORSA Immunogene Therapy, which is meant for treating patients suffering from late-stage non-small cell lung cancer in combination with Tagrisso from AstraZeneca. It is a major development for the company and one that paves the way for further development of its therapy.
Hence, it is not a surprise that the Genprex stock emerged as a major gainer following the announcement from the company. In this regard, it should also be noted that the Fast Track Designation for the Acclaim 1 patient population had been awarded by the FDA back in January 2020.
On Wednesday, GNPX stock jumped by 12.73% to $3.72 with more than 1.83 million shares, compared to its average volume of 718k shares. The stock has moved within a range of $3.4600 – 3.8860 after opening the trade at $3.48. Over the past 52-week, the stock has been trading within a range of $2.8100 – 7.7200.